XML 124 R111.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Financial Information - Cash Flows (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Cash flows from operating activities          
Net income $ 111.0 $ 282.4 $ 173.6 $ 1,126.1  
Adjustments to reconcile net income to net cash flows from operating activities:          
Depreciation and amortization     137.0 102.7  
Equity-based compensation 64.4 54.2 186.8 139.3  
Non-cash performance allocations and incentive fees, net     427.3 184.1  
Non-cash principal investment income     (91.6) (483.8)  
Other non-cash amounts     8.1 (27.4)  
Purchases of investments     (221.3) (559.6)  
Proceeds from the sale of investments     338.4 388.3  
Payments of contingent consideration     (68.6) (5.7)  
Changes in deferred taxes, net     (103.3) (2.3)  
Change in due from affiliates and other receivables     16.7 (62.6)  
Change in deposits and other     (38.5) (12.8)  
Change in accounts payable, accrued expenses and other liabilities     (101.8) (27.7)  
Change in accrued compensation and benefits     (128.3) (265.3)  
Change in due to affiliates     (8.8) 2.4  
Change in lease right-of-use asset and lease liability     (7.5) (7.0)  
Change in deferred revenue     290.0 274.9  
Net cash used in operating activities     (49.2) (258.5)  
Cash flows from investing activities          
Purchases of corporate treasury investments     (187.3) (69.6)  
Proceeds from corporate treasury investments     152.4 0.0  
Purchases of fixed assets, net     (49.6) (25.0)  
Purchase of Abingworth, net of cash acquired     0.0 (150.2)  
Purchase of CBAM intangibles and investments, net     0.0 (618.4)  
Net cash used in investing activities     (84.5) (863.2)  
Cash flows from financing activities          
Payments on CLO borrowings     (7.3) (8.9)  
Proceeds from CLO borrowings, net of financing costs     10.0 55.2  
Dividends to common stockholders     (371.4) (325.4)  
Payment of deferred consideration for Carlyle Holdings units     (68.8) (68.8)  
Contributions from non-controlling interest holders     99.0 282.1  
Distributions to non-controlling interest holders     (99.7) (173.5)  
Common shares issued for performance allocations     0.0 38.9  
Common shares repurchased     (203.7) (146.9)  
Change in due to/from affiliates financing activities     (82.7) (13.2)  
Net cash provided by financing activities     52.6 88.9  
Effect of foreign exchange rate changes     (8.2) (79.8)  
Decrease in cash, cash equivalents and restricted cash     (89.3) (1,112.6)  
Cash, cash equivalents and restricted cash, beginning of period     1,361.5 2,475.1  
Cash, cash equivalents and restricted cash, end of period 1,272.2 1,362.5 1,272.2 1,362.5  
Reconciliation of cash, cash equivalents and restricted cash, end of period:          
Cash and cash equivalents 1,267.7 1,361.9 1,267.7 1,361.9 $ 1,360.7
Restricted cash 4.5 0.6 4.5 0.6 0.8
Total cash, cash equivalents and restricted cash, end of period 1,272.2 1,362.5 1,272.2 1,362.5 1,361.5
Cash and cash equivalents held at Consolidated Funds 352.3 177.2 352.3 177.2 209.0
Consolidated Operating Entities          
Cash flows from operating activities          
Net income     104.9 1,112.1  
Adjustments to reconcile net income to net cash flows from operating activities:          
Depreciation and amortization     137.0 102.7  
Equity-based compensation     186.8 139.3  
Non-cash performance allocations and incentive fees, net     425.0 179.4  
Non-cash principal investment income     (100.0) (434.9)  
Other non-cash amounts     8.1 (27.4)  
Purchases of investments     (244.9) (582.4)  
Proceeds from the sale of investments     351.8 410.2  
Payments of contingent consideration     (68.6) (5.7)  
Changes in deferred taxes, net     (103.3) (2.3)  
Change in due from affiliates and other receivables     16.9 (62.0)  
Change in deposits and other     (38.5) (12.8)  
Change in accounts payable, accrued expenses and other liabilities     (101.8) (27.7)  
Change in accrued compensation and benefits     (128.3) (265.3)  
Change in due to affiliates     (8.8) 2.4  
Change in lease right-of-use asset and lease liability     (7.5) (7.0)  
Change in deferred revenue     290.0 274.9  
Net cash used in operating activities     718.8 793.5  
Cash flows from investing activities          
Purchases of corporate treasury investments     (187.3) (69.6)  
Proceeds from corporate treasury investments     152.4 0.0  
Purchases of fixed assets, net     (49.6) (25.0)  
Purchase of Abingworth, net of cash acquired     0.0 (150.2)  
Purchase of CBAM intangibles and investments, net     0.0 (618.4)  
Net cash used in investing activities     (84.5) (863.2)  
Cash flows from financing activities          
Payments on CLO borrowings     (7.3) (8.9)  
Proceeds from CLO borrowings, net of financing costs     10.0 55.2  
Dividends to common stockholders     (371.4) (325.4)  
Payment of deferred consideration for Carlyle Holdings units     (68.8) (68.8)  
Contributions from non-controlling interest holders     7.9 7.2  
Distributions to non-controlling interest holders     (48.9) (52.5)  
Common shares issued for performance allocations     0.0 38.9  
Common shares repurchased     (203.7) (146.9)  
Change in due to/from affiliates financing activities     (36.4) (471.6)  
Net cash provided by financing activities     (718.6) (972.8)  
Effect of foreign exchange rate changes     (5.0) (70.1)  
Decrease in cash, cash equivalents and restricted cash     (89.3) (1,112.6)  
Cash, cash equivalents and restricted cash, beginning of period     1,361.5 2,475.1  
Cash, cash equivalents and restricted cash, end of period 1,272.2 1,362.5 1,272.2 1,362.5  
Supplemental non-cash disclosures          
Issuance of common shares related to the acquisition of CBAM and Abingworth     0.0 219.5  
Reconciliation of cash, cash equivalents and restricted cash, end of period:          
Cash and cash equivalents 1,267.7 1,361.9 1,267.7 1,361.9  
Restricted cash 4.5 0.6 4.5 0.6  
Total cash, cash equivalents and restricted cash, end of period 1,272.2 1,362.5 1,272.2 1,362.5 $ 1,361.5
Cash and cash equivalents held at Consolidated Funds $ 352.3 $ 177.2 $ 352.3 $ 177.2